Targets › PTK7
4 programs from 4 companies in 4 trials: 4 Phase 1; Oncology; next expected readout Jul 2027.
Inactive tyrosine kinase involved in the Wnt signaling pathway. Component of both the non-canonical (also known as the Wnt/planar cell polarity signaling) and the canonical Wnt signaling pathways. (UniProt, Q13308)
Open in Phaseline: the race on PTK7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| IDEAYA Biosciences | IDE034 Bispecific antibody targeting B7-H3 and PTK7 | B7H3, PTK7 | Phase 1 | Esophageal Squamous Cell Carcinoma | Jul 2027 |
| Day One Biopharmaceuticals | DAY301 PTK7-directed antibody-drug conjugate | PTK7 | Phase 1 | Advanced or Metastatic Solid Tumors | Dec 2027 |
| Kivu Bioscience | KIVU-107 PTK7-directed antibody-drug conjugate | PTK7 | Phase 1 | Advance Solid Tumors | Mar 2028 |
| Whitehawk Therapeutics | HWK-007 PTK7-directed antibody-drug conjugate | PTK7 | Phase 1 | Endometrial Cancer | Oct 2028 |
Esophageal Squamous Cell Carcinoma (1) Endometrial Cancer (1) Advanced or Metastatic Solid Tumors (1) Advance Solid Tumors (1)
small molecule (4)
IDEAYA Biosciences (1) Whitehawk Therapeutics (1) Day One Biopharmaceuticals (1) Kivu Bioscience (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.